NewzenPharma is a U.S.-based, manufacturing-driven clinical-stage biotechnology company with a single-minded commitment to advancing the frontier of cancer therapeutics. Leveraging our deep expertise in targeting DNA repair mechanisms within cancer and tumor cells, we are redefining treatment options with a pioneering approach that enhances patient outcomes and clinical effectiveness.

Under the guidance of a world-class management team experienced in cell and gene therapies, NewzenPharma’s fully integrated, in-house research and development division drives discovery, translational research, and manufacturing excellence. Our focus on innovation is complemented by our global presence, where we have built a strong brand reputation in Asia and Africa. As we expand our focus on the U.S. market and beyond, NewzenPharma remains steadfast in upholding the highest standards of quality and efficacy. Our work is proudly recognized by the U.S. Food and Drug Administration (FDA), underscoring our commitment to regulatory excellence.